Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DF7Y9S
|
|||
| Drug Name |
CBP-201
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Atopic dermatitis [ICD-11: EA80; ICD-10: L20] | Phase 3 | [1] | |
| Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 2 | [2] | ||
| Company |
Connect Biopharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 4 receptor alpha (IL4R) | Target Info | Antagonist | [3] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Inflammatory bowel disease (IBD) | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| IL4 Signaling Pathway | ||||
| EGFR1 Signaling Pathway | ||||
| Panther Pathway | Interleukin signaling pathway | |||
| Pathway Interaction Database | p73 transcription factor network | |||
| IL4-mediated signaling events | ||||
| WikiPathways | Inflammatory Response Pathway | |||
| IL-4 Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05614817) A Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of CBP-201 Monotherapy in Patients With Moderate-To-Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04773678) A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Efficacy and Safety Study of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation. U.S.National Institutes of Health. | |||
| REF 3 | Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Ralpha, for the treatment of Th2 inflammatory diseases. Sci Rep. 2023 Jul 31;13(1):12411. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.